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Abstract 
The  aim  of  our  study  was  to  determine  the  importance  of  p53,  PCNA  and  Ki-67,  evaluated  by 
immunohistochemistry, in the treatment and prediction of the laryngeal carcinoma. Out of a total of 319 patients with 
laryngeal carcinoma that underwent surgery in our department between 1999 and 2007, we performed a retrospective 
study on 71 cases who benefited by immunohistochemical guidance before the beginning of the treatment. All these 
patients  have  been followed-up two to five  years after surgery.  The  values  of  p53, PCNA and Ki-67 are strongly 
correlated with the histological grading, by means of descriptive statistics (confidence level 95%); the mean values of 
these three markers corresponding  to each HP grade. A  highly  statistical significant positive correlation (r = 0.84, 
p<0.001) between the values of p53 and PCNA was observed. The values of p53, PCNA and Ki-67 in the patients from 
this study are strongly correlated with the absence of the loco-regional lymph node metastases, by means of descriptive 
statistics (confidence level 95%). Ki-67 only is correlated significantly to the presence of lymphatic metastases in the 
regional lymph nodes (stage N1, N2 or N3 TNM). P53 and PCNA are not correlated significantly with the presence of 
the metastases in the regional lymph nodes. 
 
 
Introduction 
 
We will comment upon several aspects of 
a clinical study regarding the p53, PCNA and Ki-
67 expression in laryngeal cancers. The aim of our 
study  was  to  determine  the  importance  of  these 
three  biological  markers,  evaluated  by 
immunohistochemistry,  in  the  treatment  and 
prediction of the laryngeal carcinoma. 
The  squamous  cell  carcinoma  represents 
about  90%  of  malignant  tumors  of  the  larynx, 
being  correlated  with  smoking  and  alcoholism. 
The laryngeal malignancies are more common in 
men aged 55 to 70, but women and children are 
not  excluded;  laryngeal  cancer  is  known  to  be 
responsible  for  0.9%  of  the  total  deaths  from 
cancer and is one of the most curable malignancy 
of  this  region,  because  most  of  them  are  early 
diagnosed. Laryngeal cancer cases may manifest 
local rebound or metastasis in the regional lymph 
nodes,  determining  a  significant  morbidity  and 
mortality.  Although  the  clinical  staging  is  an 
important  outcome  predictor,  there  are  many 
genetic  mutations  of  the  onco-genes  and  of  the 
tumor-suppressor  genes  which  interfere  with 
tumoral growth and these genetic influences  are 
insufficiently studied [1,2,3]. 
These  tumors  can  be  classified 
anatomically, depending on their position in the 
larynx: supraglottic, glottic and subglottic cancers. 
The  glottic  localization  has  the  best  prognosis 
because  of  its  poor  lymphatic  drainage,  slow 
tumoral  progression  and  late  metastasis.  A 
particular situation is found in the hypopharyngeal 
cancer which has lesions located in the piriform 
sinus and in the postcricoidian region. 
The histological classification is made by 
the following criteria: the cellular differentiation, 
pleiomorphism  and  architectural  abnormalities, 
the  number  of  mitosis  and  the  tumor-host 
interaction. 
For a better understanding of the growth 
and  progression  of  the  pre-neoplastic  and 
neoplastic  lesions  of  the  superior  aero-digestive 
tract,  we  studied  factors  with  previously 
demonstrated  prognostic  value  in  other  cancers, 
like  p53,  PCNA  and  Ki-67.  The  p53  protein  is 
present in all normal cells, but the half life of the 
“wild” (normal) protein is so short (6-30min) that 
does not reach high enough levels in order to be 
detected  by  the  standard  immunohistochemical 
techniques. On the other side, the mutant p53 has 
a much higher half life, so it accumulates and is Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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detected in the cellular nucleus. The alteration of 
the  p53  creates  a  mutant  p53,  which  is  also 
expressed,  but  does  not  have  the  regulatory 
function as the “wild” p53 does. The p53 positive 
cells are those that suffered mutations of the p53 
gene. Proliferation cell nuclear antigen, PCNA is 
a nuclear antigen present in the G1 and S phases 
of  the  cellular  cycle.  Low  values  of  PCNA  are 
found  in  the  basal  stratus  of  the  pavimentous 
epithelia. Ki-67 also a nuclear antigen present in 
the active phases of the cellular cycle (G1, S, G2, 
M  and  absent  in  G0),  thus  reflecting  cellular 
division; the tumors which are in cellular division 
but  spend  more  time  than  normal  will  over-
express the Ki-67 antigen. The protein of the p53 
oncogene (situated on the Cz17p chromosome) is 
an  onco-suppressive  protein  which  monitors  the 
cellular cycle. A positive correlation between the 
high proliferation rate and abnormality of p53 is 
described in literature [4–24]. 
 
Material and methods 
 
Out  of  a  total  of  319  patients  with 
laryngeal  carcinoma  operated  in  our  clinic 
between  1999  and  2007,  we  performed  a 
retrospective study on 71 cases who benefited by 
immunohistochemical  guidance  before  the 
beginning of the treatment. All these patients have 
been followed-up two to five years after surgery. 
The  tumoral  lesions  were  isolated  using 
laryngeal  endoscopy  by  debulking  biopsy  using 
classical  or  carbon  dioxide  laser  resection.  The 
biopsy samples were formalin fixed, paraffin  
 
embedded  and  examined  by  histopathology  and 
immunohistochemistry  (IHC)  at  the  “Victor 
Babes” Institute, Bucharest, Romania.  
To  ensure  the  reliability  of  the  experimental 
study, internal quality control of IHC techniques 
was performed as a part of an implemented and 
certified  quality  assurance  system  (ISO 
15189/2007). 
The  procedure  employed  consisted  in 
deparaffinization  in  xylene  and  alcohol  series, 
rehydration,  washing  in  phosphate  saline  buffer 
(PBS),  incubation  with  normal  serum,  for  20 
minutes,  incubation  with  primary  antibody 
overnight, standard labeled streptavidine-antibody 
biotin (LSAB) kit (DAKO), washing in carbonate 
buffer  and  development  in  3-3’-DAB 
hydrochloride / H2O2; immunostain amplification 
with  heavy  metals  (cobalt)  was  performed  for 
nuclear  antigens.  The  routine  stain  used  was 
Haematoxylin  and  Eosin  (H&E)  for  the 
assessment  of  the  histopathological  aspects  and 
the  mitotic  index.  The  IHC  was  performed  on 
3m  thick  sections  from  10%  formalin  fixed 
paraffin  embedded  tissues,  according  to  the 
indirect  tristadial  Avidin-Biotin-Complex 
Peroxidase method of HSU et al [25], modified by 
Bussolati and Gugliotta [26]. The selected cases 
were  tested  by  IHC  using  the  following 
antibodies: PCNA – clone PC10, dilution 1:200, 
kit source DAKO and p53 – clone DO7, dilution 
1:50, kit source Neomarkers. All specimens were 
counterstained  with  Meyer’s  haematoxylin, 
examined and photographed on a Nikon Eclipse 
600 microscope (Fig. 1-6 display examples of the 
obtained result). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. p53+ ≈ 30-40% in carcinoma in situ; P53+ 
≈ 5% in the areas with simple dysplasia; IHC, 4x. 
Fig. 2. p53+ ≈ 60% in invasive undifferentiated 
squamous cell carcinoma; p53+ ≈ 1% in the 
residual papillomatous areas; IHC, 4x. 
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The patients included in this study were 
aged between 35 and 71 years and the majority 
(90.1%) were men. The highest incidence of the 
laryngeal  carcinoma  was  identified  in  the  6
th 
decade of life – 43.7% of cases, followed by the 
7
th decade – 29.6% and the 5
th decade – 19.7%. 
The lowest incidence of the laryngeal carcinoma 
in this study was described over 71 years – 4.2% 
and under 40 years old – 2.8% of cases. 
Regarding  the  clinical  staging,  the 
majority  of  the  patients  were  diagnosed  in 
advanced  TNM  stages  –  30.99%  in  stages  IV 
TNM and 26.76% in stages III TNM. 36.6% of 
the patients had metastases in the regional lymph 
nodes (stages N1, N2 and N3 TNM) at the time of 
diagnosis.  The  glottic  invasion  was  found  in 
91.5%  of  the  patients,  supraglottic  invasion  in 
31%  and  subglottic  extension  in  11.3%  of  the 
patients.  The  histology  was  well  to  moderate 
differentiated  in  67.6%  of  the  tumors  and  poor 
differentiated or undifferentiated in 32.4% of the 
tumors. 
The  surgical  procedures  applied  after 
histological  investigations  were:  52.1%  of  the 
patients  underwent  total  laryngectomy,  40.9% 
carbon  dioxide  laser  resection  of  the  tumoral 
Fig. 3. PCNA+ ≈ 40-50% in moderate 
differentiated squamous cell carcinoma; PCNA+ 
≈ 10% at the invasion front; IHC, 4x. 
 
Fig. 4. PCNA+ ≈ 60-80% in the areas with poor 
differentiated basaloid carcinoma; PCNA+ 3-5% 
in the areas with moderate differentiated 
squamous carcinoma; IHC, 4x. 
 
Fig. 5. Ki-67+ ≈ 20% in the inferior 1/3 of the 
squamous epithelium with simple dysplasia; IHC, 
10x; 
Fig. 6. Ki-67+ in the basal stratus and ≈ 40% in 
islands of micro-invasive squamous cell 
carcinoma and carcinoma in situ; IHC, 4x. 
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lesions and 7% partial laryngectomy. 
After  the  IHC  analysis  of  the  initial 
biopsies and of the resection specimens, (margins 
of  resection,  regional  lymph  node  metastases, 
TNM  staging),  the  operated  patients  underwent 
IHC  guided  radiotherapy.  Radiotherapy  was 
applied to all the patients with metastases in the 
regional lymph nodes and to 42.2% of the patients 
without  regional  lymph  node  metastases. 
Statistically, IHC guided radiotherapy was applied 
to all patients diagnosed in stage IV TNM, as well 
as to 57.9% of those diagnosed in stage III TNM, 
42.9% of those diagnosed in stage II TNM  and 
33.3% of the patients diagnosed in stage I TNM. 
 
Results 
 
The  majority  of  the  patients  with 
squamous  laryngeal  carcinoma  from  this  study 
survived  after  IHC  guided  surgery  and 
radiotherapy – 66.2%. The tumoral rebounds and 
regional  metastases  after  surgery  were  found  in 
approx. 19% in the first six months after surgery, 
in 32% in the first two years and 49% in the first 
five years. 
Regarding the TNM staging, the highest 
survival rates were identified in the stage I TNM - 
88.9%, in the stage II TNM - 80.9% and 73.7% of 
the patients survived. The highest mortality rate 
was identified in the stage IV TNM – 63.6% of 
the  patients  included in this  study  (as  shown  in 
Chart 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The highest survival rates were obtained 
for  well  differentiated  laryngeal  carcinomas  – 
90%  of  the  patients  and  for  the  moderate 
differentiated laryngeal carcinomas – 71.05%; the 
lowest survival rates had the poor differentiated or 
undifferentiated laryngeal carcinomas – 47.8% of 
the patients survived. 
The  majority  of  the  patients  without 
regional lymph node metastases – 76.6% of those 
diagnosed  in  stage  N0  TNM  -  survived.  The 
lowest  survival  rates  were  obtained  for  the 
patients diagnosed in stage N1 TNM  – 50%, in 
stage  N2  and  N3  TNM  –  only  37.5%  for  each 
stage. Thus, the highest mortality rates are found 
in  the  patients  with  regional  lymph  nodes 
metastases – 57.7% deceased in the first two to 
fives  years  after  IHC  guided  surgery  and 
radiotherapy (as shown in Chart 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  correlation  between  the  values  of 
p53, PCNA, Ki-67 the histological grading. The 
values  of  p53,  PCNA  and  Ki-67  are  strongly 
correlated with the histological grading, by means 
of  descriptive  statistics  (confidence  level  95%); 
the  mean  values  of  these  three  markers 
corresponding to each HP grade are shown in the 
table 1. 
 
 
 
 
HP Grade 
Mean values of IHC predictors in SCLC compared with 
the HP Grade 
p53 (%)  PCNA (%)  Ki-67 (%) 
Well differentiated  13.5  37  13 
Moderate differentiated  19.2  45.1  14.9 
Poor differentiated  42.3  67.8  23.7 
 
 
Chart 1. Survival versus TNM staging 
Chart 2. Survival versus regional lymph node 
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Table 1. IHC correlation with the HP grade. 
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The correlation between p53 and PCNA in the squamous cell 
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The  correlation  between  the  values  of 
p53,  PCNA  and  Ki-67.  A  highly  statistical 
significant positive correlation (r = 0.84, p<0.001) 
between  the  values  of  p53  and  PCNA  was 
observed. The values of p53 and Ki-67 also have 
a highly statistical significant positive correlation 
(r  =  0.71,  p<0.001),  indicating  that  these  three 
factors correlated have a superior prognostic value 
when considered together (Charts 3, 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  correlation  between  the  values  of 
p53, PCNA, Ki-67 and the local metastases in 
the  regional  lymph  nodes.  The  values  of  p53, 
PCNA and Ki-67 in the patients from this study 
are  strongly  correlated  with  the  absence  of  the 
loco-regional lymph node metastases, by means of 
descriptive statistics (confidence level 95%). Ki-
67 only is correlated significantly to the presence 
of  lymphatic  metastases  in  the  regional  lymph 
nodes (stage N1, N2 or N3 TNM). P53 and PCNA 
are not correlated significantly with the presence 
of  the  metastases  in  the  regional  lymph  nodes 
(Table 2). 
Lymph metastases 
(TNM stage) 
Mean values of IHC predictors in SCLC regarding regional 
lymph node metastases 
p53 (%)  PCNA (%)  Ki-67 (%) 
N0  24  49.1  17 
N1, N2 or N3  29.2  55  18.3 
 
 
 
 
The correlation between the values of 
p53, PCNA, Ki-67 and survival. The values of 
p53, PCNA and Ki-67 are strongly correlated 
 
with  the  survival  of  patients,  by  means  of 
descriptive statistics (confidence level 95%), with 
the mean values as shown in the Table 3. 
Survival status 
 
Mean values of IHC predictors in SCLC regarding the 
therapeutic outcome 
 
p53 (%)  PCNA (%)  Ki-67 (%) 
Survivals  20.1  45.9  15.7 
Deaths  37.3  61.8  20.8 
 
 
 
Discussions 
 
Despite  the  continuous  upgrades  in 
radiotherapy  and  surgical  techniques  in  the  past 
two  decades,  the  survival  rate  in  superior  aero-
digestive tract cancers had been little influenced. 
New  predictive  factors  can  nowadays  be 
determined before any treatment or in early stages 
of the treatment to allow the distribution of patient 
in subgroup with a particular known evolution, in 
Chart 3. p53 – PCNA correlation 
The correlation between p53 and Ki-67 in the squamous cell 
laryngeal carcinoma (n=71)
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Chart 4. p53 – Ki-67 correlation 
Table 2. IHC correlation with the regional lymph node metastases. 
 
Table 3. IHC correlation with the survival status. 
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order  to  undergo  differentiated  diagnostic  and 
therapeutic protocols with better results regarding 
the overall survival. 
The evolution speed of the carcinoma and 
the risk of metastasis are proportional with local 
lymph  node  initial  invasion.  Therewith,  an 
unsolved query for the moment is the fact that at 
the same level of lymph node invasion, some of 
the  patients  develop  rapidly  metastases  whereas 
others never do. 
Laryngeal  cancers  have  diverse  types  of 
structure and evolution. This is why, in order to be 
able to establish the prognostic factors, we must 
understand the biologic evolution and the natural 
history  of  every  type  of  cancer.  It  is  also  very 
important to determine the factors closely related 
to the patient’s organism, to the tumor and to the 
therapy means we intend to use. 
The  predictive  factors  are  classified  by 
current oncology studies as follows: 
-  factors related to the tumor, to the 
peri-tumoral extension and to the TNM stage; 
-  histopathological factors: cellular 
differentiation, mitotic activity, capsular invasion 
and breakage, inflammatory peri-tumoral infiltrate 
and cervical lymph nodes invasion; 
-  biological  factors  determined  by 
immunohistochemistry:  the  onco-suppressive 
gene p53 modifications, PCNA and Ki-67 nuclear 
antigens, bcl-2 pro-oncogene, EGFR, VEGF and 
VEGF-C growth factors. 
Our  study  was  meant  to  explore  the 
correlation  between  the  over-expression  of  p53, 
PCNA,  Ki-67  and  the  tumoral  growth,  early 
lymphatic metastasis, response to surgery / radio-
therapy and overall survival. 
Based on the statistical sample analyzed, 
we  have  shown  there  is  a  strong  correlation 
between the tumoral cells with a high rate of DNA 
synthesis and the expression of PCNA and Ki-67. 
There  is  also  a  strong  relationship  between  the 
high  rate  of  cellular  proliferation  and  p53 
abnormalities. 
A  well  or  moderate  differentiated  tumor 
associated with PCNA positivism below 40% is a 
good prognosis of the disease. PCNA higher than 
40% and poorly differentiated or undifferentiated 
tumors  are  generally  correlated  with  metastasis 
and local recurrence. 
 
Conclusions 
 
The  biological  factors  of  tumoral 
aggression correlate well with the overall survival 
of the patients. Furthermore, due to the fact that 
normally all three factors analyzed occur together, 
the  correlation  of  all  factors  can  give  a  much 
stronger indication than one factor alone. 
High  values  of  positive  p53  (20-60%), 
PCNA (60-80%) and Ki-67 (higher than 40%) are 
correlated  with  a  high  biological  aggressiveness 
of  the  tumor  and  with  the  histological  grading, 
respectively  poor  differentiated  or 
undifferentiated  carcinomas.  Moderate  values  of 
positive p53 (10-20%), PCNA (40-60%) and Ki-
67  (20-40%)  are  correlated  with  a  moderate 
biological  aggressiveness  of the  tumor  and  with 
the  histological  grading,  respectively  moderate 
differentiated carcinomas. Low values of positive 
p53  (5-15%),  PCNA  (20-40%)  and  Ki-67  (20-
40%)  are  correlated  with  a  moderate  biological 
aggressiveness  of  the  tumor  and  with  the 
histological  grading,  respectively  good 
differentiated carcinomas. 
The  most  important  clinical  predictive 
factors  are  the  TNM  staging,  the  tumor 
localization and the age of the patient. 
The  majority  of  patients  studied  were 
diagnosed  with  advanced  stages  of  laryngeal 
carcinoma – stages III and IV TNM – more than 
56%  of  cases.  Late  diagnosis  on  this  statistical 
sample  has  afforded  extraction  of  representative 
statistical  data  on  the  evolution  of  the  disease, 
which  would  not  otherwise  be  available.  The 
functional and “quo ad vitam” prognosis depends 
on  the  correct  interpretation  of  the  predictive 
factors,  the  correct  staggering  of  the  therapy  – 
chemotherapy,  radiotherapy  and  surgery  –  by 
means of the tumoral grading and staging. 
A correct applied radiotherapy, guided by 
the  clinical  and  immunohistochemical  predictive 
factors  may  lead  to  better  healings,  even  for 
carcinomas  diagnosed  in  the  stage  III  TNM 
without surgical intervention. The chemotherapy 
is  useful  in  local  rebounds  or  lymphatic 
metastases after surgery. 
We have demonstrated that the treatment 
guidance  after  the  immunohistochemical 
predictive factors raises the overall survival by 30 
– 40%. The evaluation of these predictive factors 
should be made at the moment of diagnosis or in 
the early stages of the treatment. It is important to 
note that the probability of re-occurrence can also 
be evaluated based on these factors, and as such 
they are an indispensable guide in determining the 
appropriate treatment strategy. 
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